Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Kevin Forsythe"'
Autor:
Charles C L Tong, Eric C Ko, Max W Sung, Jamie A Cesaretti, Richard G Stock, Stuart H Packer, Kevin Forsythe, Eric M Genden, Myron Schwartz, K H Vincent Lau, Matthew Galsky, Junko Ozao-Choy, Shu-Hsia Chen, Johnny Kao
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e36979 (2012)
Preclinical data suggest that sunitinib enhances the efficacy of radiotherapy. We tested the combination of sunitinib and hypofractionated image-guided radiotherapy (IGRT) in a cohort of patients with historically incurable distant metastases.Twenty
Externí odkaz:
https://doaj.org/article/33d51a22ffbc45f6b39d8f42556117ca
Autor:
Thomas J. Quinn, Stephanie Daignault-Newton, Walter Bosch, Neil Mariados, John Sylvester, Dhiren Shah, Eric Gross, Richard Hudes, David Beyer, Steven Kurtzman, Jeffrey Bogart, R. Alex Hsi, Michael Kos, Rodney Ellis, Mark Logsdon, Shawn Zimberg, Kevin Forsythe, Hong Zhang, Edward Soffen, Patrick Francke, Constantine Mantz, Theodore DeWeese, Hiram A. Gay, Jeff Michalski, Daniel A. Hamstra
Publikováno v:
Practical Radiation Oncology. 10:186-194
Previously a phase III trial of a hydrogel rectal spacer during prostate radiation therapy found decreased toxicity and a clinically significant improvement in bowel quality of life (QOL) at 3 years by the Expanded Prostate Cancer Index. We performed
Autor:
Daniel A. Hamstra, Neil Mariados, John Sylvester, Dhiren Shah, Lawrence Karsh, Richard Hudes, David Beyer, Steven Kurtzman, Jeffrey Bogart, R. Alex Hsi, Michael Kos, Rodney Ellis, Mark Logsdon, Shawn Zimberg, Kevin Forsythe, Hong Zhang, Edward Soffen, Patrick Francke, Constantine Mantz, Peter Rossi, Theodore DeWeese, Stephanie Daignault-Newton, Benjamin W. Fischer-Valuck, Anupama Chundury, Hiram Gay, Walter Bosch, Jeff Michalski
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 97:976-985
SpaceOAR, a Food and Drug Administration-approved hydrogel intended to create a rectal-prostate space, was evaluated in a single-blind phase III trial of image guided intensity modulated radiation therapy. A total of 222 men were randomized 2:1 to th
Autor:
Daniel A. Hamstra, Neil Mariados, John Sylvester, Dhiren Shah, Eric Gross, Richard Hudes, David Beyer, Steven Kurtzman, Jeffrey Bogart, R. Alex Hsi, Michael Kos, Rodney Ellis, Mark Logsdon, Shawn Zimberg, Kevin Forsythe, Hong Zhang, Edward Soffen, Patrick Francke, Constantine Mantz, Peter Rossi, Theodore DeWeese, Stephanie Daignault-Newton, Benjamin W. Fischer-Valuck, Anupama Chundury, Hiram A. Gay, Walter Bosch, Jeff Michalski
Publikováno v:
Practical radiation oncology. 8(1)
We previously reported the results of a phase 3 trial evaluating a prostate/rectal hydrogel spacer during prostate intensity modulated radiation therapy, which resulted in decreased rectal dose and toxicity and less decline in bowel quality of life (
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 83:645-652
Purpose: To identify predictors of metastatic disease after brachytherapy treatment for prostate cancer. Methods and Materials: All patients who received either brachytherapy alone (implant) or brachytherapy in combination with external beam radiatio
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 83:630-635
To measure the benefits of intensity-modulated radiotherapy (IMRT) compared with three-dimensional conformal radiotherapy (3D-CRT) when used in combination with brachytherapy for the treatment of prostate cancer.We conducted a retrospective review of
Publikováno v:
Brachytherapy. 10:261-268
Purpose To evaluate the efficacy of multimodality therapy consisting of hormone therapy (HT), brachytherapy (BT), and external beam radiotherapy (EBRT) in extraprostatic prostate cancer and identify factors with predictive value. Methods and Material
Publikováno v:
Cancer/Radiothérapie. 15:221-229
Recent clinical trials of hypofractionated radiation treatment have provided critical insights into the safety and efficacy of hypofractionation. However, there remains much controversy in the field, both at the level of clinical practice and in our
Publikováno v:
Molecular Cancer Therapeutics. 7:1569-1578
Selective targeting of up-regulated integrins on tumor cells is a novel antiangiogenesis strategy for treating solid tumors. CNTO 95 is a fully human anti-αv integrin monoclonal antibody and has shown antitumor activity when used as a single agent i
Autor:
Brian J. Smith, Richard Hudes, Steven Kurtzman, Hong Zhang, Christopher Pieczonka, Christopher J. Skomra, Jeffrey A. Bogart, Constantine Mantz, Edward Soffen, L. Karsh, Misop Han, Seth A. Rosenthal, Neal D. Shore, Alex Hsi, Al Tiara, Neil Mariados, John Sylvester, Rodney J. Ellis, Lee Ponsky, C. Garo Gholodian, David C. Beyer, Mark Logsdon, Kevin Forsythe, Phillip Aliotta, Peter T. Nieh
Publikováno v:
Journal of Urology. 193